The Evolving Treatment Landscape of AML
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and is associated with poor long-term survival and a high relapse rate, mainly due to relapse and resistance to available therapies. The recent advancements in the technologies for genomic profiling, particularly next-g...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2022-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000//hbT.OH.2022.11.065 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126483872940032 |
|---|---|
| author | Sabine Blum Ulrike Bacher Thomas Pabst |
| author_facet | Sabine Blum Ulrike Bacher Thomas Pabst |
| author_sort | Sabine Blum |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and is associated with poor long-term survival and a high relapse rate, mainly due to relapse and resistance to available therapies. The recent advancements in the technologies for genomic profiling, particularly next-generation sequencing (NGS), have enabled the identification of recurrent and novel genetic mutations implicated in the pathogenesis of AML. This resulted in refined risk stratification and the development of more effective targeted therapies, like FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors. Over the last years, B-cell lymphoma-2 (BCL-2), a key regulator of the intrinsic apoptotic pathway, has also emerged as a relevant target for therapy for many diseases including AML, and promising results were reported with the use of BCL-2 inhibitors. This article will present an overview of some recent breakthroughs in the field of AML, with a focus on the latest drug approvals in AML. The assessment of minimal/measurable residual disease (MRD) and its role in treatment decision-making will also be briefly discussed. |
| format | Article |
| id | doaj-art-295dbcb9824b4c5f9d63ace73d65be3d |
| institution | Kabale University |
| issn | 2673-2106 |
| language | English |
| publishDate | 2022-03-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-295dbcb9824b4c5f9d63ace73d65be3d2024-12-12T17:11:11ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-21062022-03-01111The Evolving Treatment Landscape of AMLSabine BlumUlrike BacherThomas PabstAcute myeloid leukemia (AML) is the most common type of acute leukemia in adults and is associated with poor long-term survival and a high relapse rate, mainly due to relapse and resistance to available therapies. The recent advancements in the technologies for genomic profiling, particularly next-generation sequencing (NGS), have enabled the identification of recurrent and novel genetic mutations implicated in the pathogenesis of AML. This resulted in refined risk stratification and the development of more effective targeted therapies, like FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors. Over the last years, B-cell lymphoma-2 (BCL-2), a key regulator of the intrinsic apoptotic pathway, has also emerged as a relevant target for therapy for many diseases including AML, and promising results were reported with the use of BCL-2 inhibitors. This article will present an overview of some recent breakthroughs in the field of AML, with a focus on the latest drug approvals in AML. The assessment of minimal/measurable residual disease (MRD) and its role in treatment decision-making will also be briefly discussed.https://doi.org/10.36000//hbT.OH.2022.11.065 |
| spellingShingle | Sabine Blum Ulrike Bacher Thomas Pabst The Evolving Treatment Landscape of AML healthbook TIMES. Oncology Hematology |
| title | The Evolving Treatment Landscape of AML |
| title_full | The Evolving Treatment Landscape of AML |
| title_fullStr | The Evolving Treatment Landscape of AML |
| title_full_unstemmed | The Evolving Treatment Landscape of AML |
| title_short | The Evolving Treatment Landscape of AML |
| title_sort | evolving treatment landscape of aml |
| url | https://doi.org/10.36000//hbT.OH.2022.11.065 |
| work_keys_str_mv | AT sabineblum theevolvingtreatmentlandscapeofaml AT ulrikebacher theevolvingtreatmentlandscapeofaml AT thomaspabst theevolvingtreatmentlandscapeofaml AT sabineblum evolvingtreatmentlandscapeofaml AT ulrikebacher evolvingtreatmentlandscapeofaml AT thomaspabst evolvingtreatmentlandscapeofaml |